B
Bull
Bull · 25%ABVC
$3.35
Scenario price
$0.830
+0.036 (+4.31%)At close
Loading chart…
- High
- 0.850
- Open
- 0.840
- VWAP
- 0.83
- Vol
- 94.14K
- Mkt Cap
- 8.88M
- Low
- 0.810
- Amount
- 78.13K
- EV/EBITDA, TTM
- 0.00
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
AI analysis of ABVC Biopharma Inc (ABVC)
sellABVC Biopharma Inc is not a good buy right now due to its significant financial losses and declining stock performance. The current price is $0.83, which is down 62.10% year-to-date and 69.60% over the past year. Additionally, the company reported a net income loss of $2,225,022 in Q2 2025, indicating ongoing financial struggles. The main risk is the low current ratio of 0.07, suggesting liquidity issues.
Valuation Metrics
The current forward P/E ratio for ABVC Biopharma Inc (ABVC) is 0.00, compared to its 5-year average forward P/E of -2.39.
Alphio AI Price Scenarios for ABVC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.501-15NASDAQ.COMPlus Therapeutics Prices Public Offering, Raising $15 Million
9.009-23Yahoo FinanceABVC BioPharma, Inc. (ABVC) Sees 103% Increase in Assets, Preparing for Phase III Trials of Depression Treatments
9.508-14NASDAQ.COMAbvc BioPharma Doubles Assets in Q2
9.012-19NewsfilterABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
- 7.512-11Newsfilter
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
ABVC FAQ — answered by Alphio AI
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
ABVC Biopharma Inc is not a good buy right now due to its significant financial losses and declining stock performance. The current price is $0.83, which is down 62.10% year-to-date and 69.60% over the past year. Additionally, the company reported a net income loss of $2,225,022 in Q2 2025, indicating ongoing financial struggles. The main risk is the low current ratio of 0.07, suggesting liquidity issues.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。